ASAIO J. 2018 Mar/Apr;64(2):135-139. doi: 10.1097/MAT.0000000000000650.
Lung transplant is the only therapy for several end-stage lung diseases; however, the number of donated lungs suitable for transplant is not sufficient, and hundreds of patients have died waiting for an organ. Ex vivo lung perfusion (EVLP) has emerged as a new technology with the potential of reconditioning human donor lungs previously unsuitable for transplantation. Since the first successful transplant of a lung treated using EVLP in the year 2000, multiple clinical trials have demonstrated, in several transplant centers around the word, the feasibility and the potential of EVLP to increase the total number of lungs available for transplant.
肺移植是治疗几种终末期肺病的唯一方法；然而，适合移植的供肺数量不足，数以百计的患者在等待器官移植时死亡。离体肺灌注 (EVLP) 作为一种新技术已经出现，它有可能对以前不适合移植的人类供肺进行再处理。自 2000 年首次成功移植使用 EVLP 治疗的肺以来，多个临床试验已经在世界各地的多个移植中心证明了 EVLP 增加可用于移植的肺总数的可行性和潜力。
